Inmune Bio (INMB)
NASDAQ:INMB
Want to see INMB full AI Analyst Report?
INMB Stock Chart & Stats
$1.53
-$0.22(-3.95%)
At close: 4:00 PM EST
$1.53
-$0.22(-3.95%)
Day’s Range― - ―
52-Week Range$1.09 - $11.64
Previous CloseN/A
Volume114.20K
Average Volume (3M)459.75K
Market Cap
$35.09M
Enterprise Value$11.38M
Total Cash (Recent Filing)$24.75M
Total Debt (Recent Filing)$1.03M
Price to Earnings (P/E)―
Beta1.06
Next Earnings
May 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.20
Shares Outstanding26,585,258
10 Day Avg. Volume306,670
30 Day Avg. Volume459,751
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.76
Price to Sales (P/S)829.46
P/FCF Ratio-1.76
Enterprise Value/Market Cap0.32
Enterprise Value/Revenue227.51
Enterprise Value/Gross Profit-334.57
Enterprise Value/Ebitda-0.38
Forecast
1Y Price Target
$8.00Price Target Upside422.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.85
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Design And Biomarker StrategyFDA alignment on a Phase 2b/3 design for XPro with a biomarker‑driven enrollment strategy and a CDR‑SB primary endpoint, combined with positive biomarker‑defined subgroup signals, strengthens the program's path to a pivotal readout and partner interest.
Financial RunwayAnalyst notes the company reported sufficient cash to fund operations through upcoming clinical and regulatory milestones, reducing immediate pressure to raise capital.
Regulatory PathwaySubmission of a pre‑submission package to the UK regulator for CORDstrom and plans to follow with European and U.S. filings create a defined pathway toward potential marketing authorization.
Bears Say
Funding RiskConcerns about limited cash after the prior setback create funding risk that could require dilutive financing and weigh on the stock ahead of key events.
Investor Sentiment And Valuation PressureDepressed share performance and heightened investor sensitivity could constrain partner interest and keep valuation pressured until clear, convincing clinical evidence is delivered.
Prior Trial FailureA previous Phase 2 Alzheimer's trial missed its primary endpoints, which contributed to a meaningful share price pullback and higher investor skepticism toward future results.
Inmune Bio News
INMB FAQ
What was Inmune Bio’s price range in the past 12 months?
Inmune Bio lowest stock price was $1.09 and its highest was $11.64 in the past 12 months.
What is Inmune Bio’s market cap?
Inmune Bio’s market cap is $35.09M.
When is Inmune Bio’s upcoming earnings report date?
Inmune Bio’s upcoming earnings report date is May 06, 2026 which is in 19 days.
How were Inmune Bio’s earnings last quarter?
Inmune Bio released its earnings results on Mar 30, 2026. The company reported -$0.198 earnings per share for the quarter, beating the consensus estimate of -$0.27 by $0.072.
Is Inmune Bio overvalued?
According to Wall Street analysts Inmune Bio’s price is currently Undervalued.
Does Inmune Bio pay dividends?
Inmune Bio does not currently pay dividends.
What is Inmune Bio’s EPS estimate?
Inmune Bio’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Inmune Bio have?
Inmune Bio has 26,585,258 shares outstanding.
What happened to Inmune Bio’s price movement after its last earnings report?
Inmune Bio reported an EPS of -$0.198 in its last earnings report, beating expectations of -$0.27. Following the earnings report the stock price went down -0.877%.
Which hedge fund is a major shareholder of Inmune Bio?
Currently, no hedge funds are holding shares in INMB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inmune Bio Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.00 (422.88% Upside)
$8.00 (422.88% Upside)
Blogger Sentiment
Bullish
INMB Sentiment 70%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 0.3%
Last 30 Days ▼ 0.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-82.32%
12-Months-Change
Fundamentals
Return on Equity
-171.01%
Trailing 12-Months
Asset Growth
-18.23%
Trailing 12-Months
Company Description
Inmune Bio
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
INMB Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented balanced, tangible progress on high-value clinical and regulatory fronts — notably CORDStrom's convincing RDEB data, manufacturing/CMC readiness, and INKmune Phase II success — and meaningful regulatory alignment for XPro's next-stage plan. However, these positives are tempered by a missed top-line primary endpoint for MINDFuL (leading to a $16.5M impairment), an increased net loss, a modest cash balance (~$24.8M) with runway only through Q1 2027, and the need for additional capital/partnerships and incremental CMC work for U.S. filings. Overall, the company has promising technical and regulatory momentum but faces near-term financial and execution risks that keep the picture balanced.View all INMB earnings summariesINMB Stock 12 Month Forecast
Average Price Target
$8.00
▲(422.88% Upside)
Technical Analysis
Veru
―
Karyopharm Therapeutics
―
Cue Biopharma
―
Celularity
―
Jupiter Neurosciences, Inc.
―
Ownership Overview
11.17%
Insiders
4.83% Mutual Funds
2.33% Other Institutional Investors
75.96% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---